DNMT3A and cyclic hematopoiesis: The effect is the strongest for CH with presumed leukemic driver mutations, such as in the epigenetic modifier gene DNMT3A, and increases with CH clone size conventionally quantified by calculating variant allele frequency (Bowman et al., 2018; Jaiswal and Ebert, 2019; Köhnke and Majeti, 2021; Steensma et al., 2015).